[{"id":"676dfb5a-6692-4639-bd2b-6232077e3caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896335","created_at":"2021-01-18T14:12:49.075Z","updated_at":"2025-02-25T16:05:12.381Z","phase":"Phase 2","brief_title":"Palbociclib and Pembrolizumab in Central Nervous System Metastases","source_id_and_acronym":"NCT02896335","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" CCNE1 amplification • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-11-21"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"3fe15ba6-c8bd-43a0-9070-1c6451e7aaf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310879","created_at":"2021-01-18T16:21:04.198Z","updated_at":"2024-07-02T16:35:20.810Z","phase":"Phase 2","brief_title":"Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6","source_id_and_acronym":"NCT03310879","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/21/2017","start_date":" 11/21/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-02-06"},{"id":"94cef9a0-473d-4fec-a16e-315cc93497bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439201","created_at":"2021-01-18T21:22:08.104Z","updated_at":"2024-07-02T16:35:24.259Z","phase":"Phase 2","brief_title":"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)","source_id_and_acronym":"NCT04439201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 amplification","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 03/09/2021","primary_completion_date":" 03/09/2021","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-08"},{"id":"b39d6f05-f231-4745-aadd-73899fae2d7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594005","created_at":"2021-01-19T20:29:03.455Z","updated_at":"2024-07-02T16:35:34.460Z","phase":"Phase 1/2","brief_title":"CDK4/6 Tumor, Abemaciclib, Paclitaxel","source_id_and_acronym":"NCT04594005","lead_sponsor":"Yonsei University","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/25/2021","start_date":" 02/25/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2023-10-06"},{"id":"4d8abee9-1474-4364-a705-95320d1ba771","acronym":"ABORL","url":"https://clinicaltrials.gov/study/NCT03356223","created_at":"2021-01-18T16:34:03.658Z","updated_at":"2024-07-02T16:35:54.832Z","phase":"Phase 2","brief_title":"Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6","source_id_and_acronym":"NCT03356223 - ABORL","lead_sponsor":"Centre Leon Berard","biomarkers":" CDKN2A • CCND1","pipe":" | ","alterations":" CDKN2A deletion • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 11/05/2022","primary_completion_date":" 11/05/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-02-23"},{"id":"6accad76-76f1-4451-99f2-1a7ef5af528e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03344536","created_at":"2021-01-18T16:31:01.100Z","updated_at":"2024-07-02T16:35:59.970Z","phase":"Phase 1/2","brief_title":"A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT03344536","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR • FGFR • CCND1 • FGF3","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification","tags":["HER-2 • ER • PGR • FGFR • CCND1 • FGF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • zoligratinib (Debio 1347)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/10/2017","start_date":" 11/10/2017","primary_txt":" Primary completion: 08/12/2021","primary_completion_date":" 08/12/2021","study_txt":" Completion: 08/12/2021","study_completion_date":" 08/12/2021","last_update_posted":"2022-11-24"},{"id":"4ccc2c43-cf80-4471-8f20-ea4d38f5f9ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01037790","created_at":"2021-01-18T04:04:21.968Z","updated_at":"2024-07-02T16:36:33.413Z","phase":"Phase 2","brief_title":"Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer","source_id_and_acronym":"NCT01037790","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2","pipe":" | ","alterations":" KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation","tags":["HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2021-03-11"},{"id":"d9647efa-6dba-4ed2-9078-09dab597255d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00721409","created_at":"2021-01-18T02:42:27.377Z","updated_at":"2024-07-02T16:36:53.993Z","phase":"Phase 2","brief_title":"Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT00721409","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • CDKN2A • CCND1","pipe":" | ","alterations":" ER positive • HER-2 negative • CCND1 amplification • CCND1 expression • ER positive + HER-2 negative","tags":["HER-2 • ER • CDKN2A • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CCND1 amplification • CCND1 expression • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 09/15/2008","start_date":" 09/15/2008","primary_txt":" Primary completion: 11/29/2013","primary_completion_date":" 11/29/2013","study_txt":" Completion: 12/20/2017","study_completion_date":" 12/20/2017","last_update_posted":"2019-11-04"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"},{"id":"c1c59569-4d0e-46ee-bb17-66b111568989","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454919","created_at":"2021-01-18T17:02:06.573Z","updated_at":"2024-07-02T16:37:13.272Z","phase":"Phase 2","brief_title":"Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations","source_id_and_acronym":"NCT03454919","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" CDKN2A • CCND1 • CDK4","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2018-03-06"}]